en · de · es · fr · pt
hplc-notes.peptides6088.com › News › Thymosin Beta-4 Fragment Identity — Complete Guide

Thymosin Beta-4 Fragment Identity — Complete Guide

By Editorial Desk · published 2025-11-28 · last reviewed 2025-12-16 · News

The short version of thymosin beta-4 fragment fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Identity and Research Background

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Tb-500 at a glance

PropertyValueNotes
Molecular massApproximately 4963 Da for full-length thymosin beta-4Value applies to the parent protein; fragment products may differ
AppearanceWhite to off-white lyophilized powderTypical form of supplied synthetic peptide
SolubilityFreely soluble in waterPolar peptide; dissolves readily in aqueous buffer
Storage of dry powder−20 °C, desiccated, protected from lightStandard laboratory practice for peptides
Typical detection methodLiquid chromatography–tandem mass spectrometryUsed in purity testing and anti-doping analysis

TB-500 Identity and Chemical Background

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Related pages on this site

Handling, Storage and Quality Checks

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.

Handling, Storage, and Analysis

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Handling, Storage and Analytical Checks

Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.

Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.

Supporting material

Ph-S-CH3 + H2O2 → Ph-S(O)-CH3 + H2O Alkaline hydrogen peroxide is used for epoxidation of electron-deficient alkenes such as acrylic acid derivatives, and for the oxidation of alkylboranes to alcohols, the second step of hydroboration-oxidation. It is also the principal reagent in the Dakin oxidation process.

In September 1986, the band parted ways with manager Alan McGee, and came close to splitting up later in the year, with Jim Reid suffering from "exhaustion". John Moore had become an established member, but moved to rhythm guitar, with former Redskins member Martin Hewes joining the band briefly (although he strongly denies ever joining) and former Dead Can Dance percussionist James Pinker taking over on drums. Blanco y Negro manager Geoff Travis took over management duties, and the band returned in December with two gigs at the National Ballroom in Kilburn, London where they premiered new songs including "April Skies" and "Hit". Early in 1987, they entered the studio to record their second album. The first fruits of these sessions were released on the "April Skies" single in April, which saw the band have their first top ten hit. The Beach Boys influence was evident on the B-side, which included "Kill Surf City", a reworking of Brian Wilson's "Surf City". The various formats released also included a cover of Bo Diddley's "Who Do You Love?", a tribute to him with "Bo Diddley is Jesus", and a live version of Can's "Mushroom". "Happy When It Rains" was the second pre-album single, strongly influenced by Smokey Robinson's "My Girl", but it failed to match the success of "April Skies", only reaching number twenty-five. The band set out on another UK tour, this time with sets stretching to 45 minutes, although to a mixed reaction from the music press. They toured without a drummer, instead using a drum machine.

== Cultural references == British archaeologist and anthropologist Don Brothwell's The Bog Man and the Archaeology of People provides an account of the modern scientific techniques employed to conserve and analyse Lindow Man. Celtic history, language and lore scholar Anne Ross and archaeological chemist Don Robins's The Life and Death of a Druid Prince provides an account of the circumstances surrounding Lindow Man's life and death, in part hypothesising that he had lived as a highborn, perhaps even as a druid who was sacrificed to the gods at the time of the Menai Massacre and Boudica's rebellion.

=== South American Jaguars === The Jaguars consisted mainly of Argentine rugby players, but also with some from Uruguay, Brazil, Paraguay, Chile and Spain. While many of these countries suffered from dictatorships, they too had sporting bans of a sort. The Jaguars were not officially recognised by Union Argentina de Rugby, a stratagem to elude the prohibition of the Argentine government that since the early 1970s forbade any official relationship between any Argentine sport federation and South African and Rhodesian ones, due to the politics of those countries. This ostracism started in 1971 when the Argentine government forbade the Pumas to play a match in Rhodesia during the tour in South Africa.

single-nucleotide polymorphism (SNP) Any substitution of a single nucleotide which occurs at a specific position within a genome and with measurable frequency within a population; for example, at a specific base position in a DNA sequence, the majority of the individuals in a population may have a cytosine (C), while in a minority of individuals, the same position may be occupied by an adenine (A). SNPs are usually defined with respect to a "standard" reference genome; an individual human genome differs from the reference human genome at an average of 4 to 5 million positions, most of which consist of SNPs and short indels. See also polymorphism.

Sources: en.wikipedia.org

Notes from published material

== Society and culture == Genuine owns two different tradenames for this medication: 双新艾克 (literally "dual new AIDS inhibitor") for HIV use and 捷倍安 (literally "fast extra safe") for COVID use. No generics are available. Geniune holds one patent related to the drug: the original 2007 patent on the entire class of 2'-fluorine-4'-substituted nucleotides, purchased from Zhengzhou University. Two other Chinese patents on synthesizing the drug are found on Google Patents, but the owners do not appear to be connected to Geniune. Roche held one 2002 patent, CNA028118480A (CN1516590A), over the broader class of 4'-substituted nucleotides. The patent was voided in 2019 after Riboscience, its new holder, stopped paying fees.

== Related problems and reformulations == The hypercycle concept has been continuously studied since its origin. Shortly after Eigen and Schuster published their main work regarding hypercycles, John Maynard Smith raised an objection that the catalytic support for the replication given to other molecules is altruistic. Therefore, it cannot be selected and maintained in a system. He also underlined hypercycle vulnerability to parasites, as they are favoured by selection. Later on, Josef Hofbauer and Karl Sigmund indicated that in reality, a hypercycle can maintain only fewer than five members. In agreement with Eigen and Schuster's principal analysis, they argued that systems with five or more species exhibit limited and unstable cyclic behaviour, because some species can die out due to stochastic events and break the positive feedback loop that sustains the hypercycle. The extinction of the hypercycle then follows. It was also emphasized that a hypercycle size of up to four is too small to maintain the amount of information sufficient to cross the information threshold. Several researchers proposed a solution to these problems by introducing space into the initial model either explicitly or in the form of a spatial segregation within compartments. Bresch et al. proposed a package model as a solution for the parasite problem. Later on, Szathmáry and Demeter proposed a stochastic corrector machine model. Both compartmentalized systems proved to be robust against parasites.

Researchers and practitioners have introduced in the 2020s the term and concept of AI guardrails to describe different frameworks or tools designed to ensure that AI systems remain safe, as well as aligned with ethical or legal expectations. McKinsey has developed a classification of guardrails based on the different types of risks they address. This taxonomy includes for instance appropriateness guardrails, regulatory-compliance, alignment and validation guardrails.

== External links == National Library of Medicine, Toxicology Tutor II, Influence of Route of Exposure Archived 2010-06-11 at the Wayback Machine Herman TF, Santos C. First Pass Effect. 2022 Sep 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID 31869143.

== Applications == Acetonitrile is used mainly as a solvent in the purification of butadiene in refineries. Specifically, acetonitrile is fed into the top of a distillation column filled with hydrocarbons including butadiene, and as the acetonitrile falls down through the column, it absorbs the butadiene which is then sent from the bottom of the tower to a second separating tower. Heat is then employed in the separating tower to separate the butadiene. In the laboratory, it is used as a medium-polarity non-protic solvent that is miscible with water and a range of organic solvents, but not saturated hydrocarbons. It has a convenient range of temperatures at which it is a liquid, and dissolves a wide range of ionic and nonpolar compounds and is useful as a mobile phase in HPLC and LC–MS. It is widely used in battery applications because of its relatively high dielectric constant and ability to dissolve electrolytes. For similar reasons, it is a popular solvent in cyclic voltammetry. Its ultraviolet transparency UV cutoff, low viscosity and low chemical reactivity make it a popular choice for high-performance liquid chromatography (HPLC). Acetonitrile plays a significant role as the dominant solvent used in oligonucleotide synthesis from nucleoside phosphoramidites. Industrially, it is used as a solvent for the manufacture of pharmaceuticals and photographic film.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Has any regulator approved TB-500 for medical use?

No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.

Why does TB-500 appear in anti-doping literature?

It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

Network